U.S. pharma big copyright scrapped two experimental weight loss tablets last 12 months—a after-day by day capsule, lotiglipron, due to elevated liver enzymes in addition to a twice-each day tablet, danuglipron, due to potent Uncomfortable side effects—but CEO Albert Bourla has stated the company is determined to “Perform and acquire” while